Back to discover
Disease
Pericarditis
Late-stage therapeutic developmentEmerging researchSteady momentum
4
Publications
15
Clinical trials
3
Related conditions
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Cardiovascular toxicity of immune therapies for cancer.
Research2024-05-15BMJ (Clinical research ed.)
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).
Research2020-07-01JAMA cardiology
Research2015-08-29European heart journal
Research2015-08-29European heart journal
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
- Q3 2026CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial
- Q4 2027A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies
- Q4 2027A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis
- Q4 2027A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-06-08
Upcoming trial readoutHigh impact
Results expected Q3 20262026-06-03
Clinical MilestonesViewHide
Results expected
- 2026-07-09A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard TherapiesResults expected Q4 2027
- 2026-06-08A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent PericarditisResults expected Q4 2027
- 2026-06-03CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled TrialResults expected Q3 2026
- 2026-05-22A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent PericarditisResults expected Q4 2027
Recently completed
- 2026-01-01An Open-Label Clinical Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisPrimary completion
- 2025-09-15IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous PericarditisPrimary completion
Activity timeline6
- 2026-07-09ClinicalA Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard TherapiesResults expected Q4 2027
- 2026-06-08ClinicalA Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent PericarditisResults expected Q4 2027
- 2026-06-03ClinicalCardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled TrialResults expected Q3 2026
- 2026-05-22ClinicalA Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent PericarditisResults expected Q4 2027
- 2026-01-01ClinicalAn Open-Label Clinical Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisPrimary completion
- 2025-09-15ClinicalIMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous PericarditisPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
15
6
10
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20152024
Most influential
Recent publications
Major themes7
- Betacoronavirus1
- Cardiac Tamponade1
- Immune Checkpoint Inhibitors1
- Immunotherapy, Adoptive1
- Neoplasms1
- Pericardial Effusion1
- Pericarditis1
Leading journals3
- European heart journal2
- BMJ (Clinical research ed.)1
- JAMA cardiology1
Leading researchers8
- Adamo M1
- Adler Y1
- Ali HJ1
- Ammirati E1
- Antunes MJ1
- Badano L1
- Barón-Esquivias G1
- Bogaert J1
Affiliations (unnormalised)6
- "De Gasperis" Cardio Center and Transplant Center1
- "Ospedali Riuniti" and University of Trieste1
- Institute of Cardiology1
- Institute of Radiology1
- Lahey Hospital and Medical Center1
- University of Texas MD Anderson Cancer Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.